CAS: 33252-28-7; 6-Chloronicotinonitrile

相似化合物

23100-12-1 5326-23-8 6271-78-9

上下游产品

CAS号6271-78-9 6-氯烟酰胺 | CAS号170727-01-2 6-chloronicotin... | CAS号35520-41-3 反式-3-(二甲氨基)丙烯腈 | CAS号23100-12-1 6-氯吡啶-3-甲醛 | CAS号53939-30-3 5-溴-2-氯吡啶 | CAS号55305-43-6 N-氰基-4-甲基-N-苯基苯磺酰胺 | CAS号94805-52-4 3-氰基-6-吡啶酮 | CAS号58757-38-3 6-氯吡啶-3-羰酰氯 | CAS号5326-23-8 6-氯烟酸 | CAS号100-54-9 3-氰基吡啶 | CAS号354824-17-2 5-氨甲基-N,N-二甲基吡啶-2-胺 | CAS号937601-80-4 6-(THIOPHEN-3-Y... | CAS号39065-54-8 6-苯基烟腈 | CAS号4214-73-7 2-氨基-5-氰基吡啶 | CAS号1802-28-4 2,2-联吡啶-5-甲腈 | CAS号285119-72-4 ((6-氯吡啶-3-基)甲基)... | CAS号97004-04-1 5-氨基甲基-2-氯吡啶 | CAS号851340-81-3 6-(4-甲酰基苯基)烟腈 | CAS号99902-72-4 6-苯氧基烟腈 | CAS号5326-23-8 6-氯烟酸

3-氰基-6-羟基吡啶置于n,N-二甲基甲酰胺 氯化亚砜体系中,用95%的收率获得产物6-氯-3-氰基吡啶
参考文献:Practical Synthesis Of (6-Chloro-3-Pyridyl)Methylamine By Highly Selective Hydrogenation Of 6-Chloro-3-Pyridinecarbonitrile With Improved Raney Nickel Catalyst
标题:Practical Synthesis Of (6-Chloro-3-Pyridyl)Methylamine By Highly Selective Hydrogenation Of 6-Chloro-3-Pyridinecarbonitrile With Improved Raney Nickel Catalyst
摘要:本文描述了一种实用合成(6-氯-3-吡啶基)甲胺(1)的方法,该化合物是新烟碱类杀虫剂的重要中间体,采用对6-氯-3-吡啶腈(4)进行高度选择性的加氢反应.使用改进的raney镍催化剂,该催化剂由低镍含量合金(镍38%,铝62%)制备,并在浸出铝后在水中进行热处理(98°C,2小时),对4的选择性加氢反应非常有效.使用该催化剂对4进行加氢反应是在乙醇-水 [6:1 (V/v)] 和氨气的条件下,于50oc和1.2-1.4 Kg Cm-2的氢气压力下进行的,最终得到1的产率为86%,并反应生成脱氯副产物3-吡啶基甲胺,产率为2%.
DOI:10.1246/bcsj.73.1227

专利信息

专利号:US-2016090360-A1
优先权日:2013-04-26
标题:Synthesis of bace inhibitors
发明人：FETTES ALEC; MARTY HANS-PETER; SCALONE MICHELANGELO
权利人:HOFFMANN LA ROCHE
摘要:The present invention provides a one step carbonylation of a compound of formula II in the presence of water to afford a compound of formula (I), useful in processes to manufacture BACE inhibitors.

专利号:US-2024383853-A1
优先权日:2021-09-28
标题:Oximes and their use in treatment of gba-related diseases
发明人：NEVE SØREN; BROWN WILLIAM DALBY; THIRSTRUP KENNETH
权利人:ZEVRA DENMARK AS
摘要:The present invention relates to oximes, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.

专利号:US-2009170828-A1
优先权日:2006-06-12
标题:Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
发明人：ISABEL ELISE; OBALLA RENATA; POWELL DAVID; ROBICHAUD JOEL
权利人:ISABEL ELISE; OBALLA RENATA; POWELL DAVID; ROBICHAUD JOEL
摘要:Azetidine derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver steatosis; and non-alcoholic steatohepatitis. (I)

专利号:US-11279687-B2
优先权日:2010-09-03
标题:Compounds and compositions for the inhibition of NAMPT
发明人：BAIR KENNETH W; BAUMEISTER TIMM R; BUCKMELTER ALEXANDRE J; CLODFELTER KARL H; HAN BINGSONG; LIN JIAN; REYNOLDS DOMINIC J; SMITH CHASE C; WANG ZHONGGUO; ZHENG XIAOZHANG; YUEN PO-WAI
权利人:VALO HEALTH INC; GENENTECH INC
摘要:The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.

专利号:CA-2909136-A1
优先权日:2013-04-26
标题 :Synthesis of bace inhibitors

专利号:US-8404670-B2
优先权日:2009-02-11
标题:Histamine H3 inverse agonists and antagonists and methods of use thereof
发明人：CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.